TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

Pomerantz LLP announced investigations into securities fraud claims on behalf of investors in three biotech companies. Zenas BioPharma's stock plummeted 51.86% following disappointing Phase 3 trial results for obexelimab, with the CEO acknowledging the drug's efficacy fell short of expectations, triggering an additional 8.49% decline. Similar investigations were initiated for Instil Bio and Corcept Therapeutics.

Insights
JPMpJ   neutral

Mentioned as a client of Semrush, no direct impact from the acquisition


ZBIO   negative

Company issued misleading characterization of Phase 3 trial results as 'positive' when efficacy fell short of commercial viability thresholds. Stock declined 51.86% on announcement and another 8.49% when CEO acknowledged disappointment with results. Securities fraud investigation initiated.